Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

GRALISE EXTENDED RELEASE TABLETS 300 MG - HSA Drug Approval Details

Approvals/HSA/GRALISE EXTENDED RELEASE TABLETS 300 MG

Approved

THERAPEUTIC

GRALISE EXTENDED RELEASE TABLETS 300 MG

Norwich Pharmaceuticals, Inc.🇸🇬 Health Sciences Authority

Approval Date: Jan 16, 2025
Approval ID: 4919567f44b62a7b
Company: Norwich Pharmaceuticals, Inc.
Type: Therapeutic

Approval Details

Approval Id: 4919567f44b62a7b
Drug Name: GRALISE EXTENDED RELEASE TABLETS 300 MG
Product Name: GRALISE EXTENDED RELEASE TABLETS 300 MG
Approval Number: SIN17166P
Approval Date: 2025-01-16
Registrant: LOTUS INTERNATIONAL PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET, EXTENDED RELEASE
Route Of Administration: ORAL
Atc Code: N02BF01
Pharma Manufacturer Name: LOTUS INTERNATIONAL PTE. LTD.
Company Detail Path: /organization/3735e40f596a2f70/lotus-international-pte-ltd

Active Ingredients

Gabapentin

300.00 mg

Gabapentin

300.00 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 16, 2025

Approval ID

4919567f44b62a7b

Type

Therapeutic

Back to HSA Approvals